The Food and Drug Administration approved belzutifan, or Welireg, marketed by Merck (MRK), for adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma, or PPGL. “This represents the first FDA approval of an oral therapy for PPGL,” the FDA stated.

Confident Investing Starts Here:

Quickly and easily unpack a company's performance  with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox  with TipRanks' Smart Value Newsletter

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on MRK:

Disclaimer & DisclosureReport an Issue

Jefferies not seeing significant impact to Merck, Bristol from draft guidance UnitedHealth, Wayfair downgraded: Wall Street’s top analyst calls SCHD ETF News, 5/14/2025 U.S. biotech companies debate relocating trials outside U.S., Reuters reports Merck downgraded to Neutral from Buy at Citi

View Comments